Read our Recent Headlines

July 27 Biotech Update

We are in the midst of a busy week but we have a slight pause in the news but will pick up soon enough. The sector held up amazingly well.

July 26 Biotech Update

We got a double barrel of bad news after the close last night but I must say the overall sector reaction is good. I have said this before but it.

July 25 Biotech Update

It is a slow start to what will end up being a very busy week of large cap earnings. We have a large cap reporting every day and it will.

July 22 Biotech Update

Not a lot of additional news today. The sector continues to modestly outperform the broad market, which is good. The XBI crossed over the 200 day moving average (and actually.

July 21 Biotech Update

Finally we get some news for the sector and it is good news. Yesterday was a good day and the news so far today only builds on that move. Perhaps.

Dave-Trading – July Edition – Unveiling the “whipped cream” strategy

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

July 20 Biotech Update

So the sector might actually be outperforming the market today but it is early. What is nice is that the positive news continues to be rewarded, which means our holdings.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!